allergy treatment News
-
Allovate Therapeutics Announces Issuance of U.S. Patent Covering Novel Oral Mucosal Immunotherapy Platform
Allovate Therapeutics, a biopharmaceutical company focused on improving treatment for allergies, announced today that the U.S Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,271,899 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” The issuing patent including claims to the approach of combining allergenic proteins with ...
-
Restore Health Selected To Provide Innovative Allergy Toothpaste System: Allerdent
Allovate, LLC, has signed an agreement with Restore Health, a company specializing in personalized medicine, for the exclusive rights to provide Allerdent™, a new personalized therapeutic toothpaste system for people suffering from allergic rhinitis. Allerdent™ is designed for daily use as part of a normal tooth-brushing regimen and enables allergy sufferers to incorporate ...
-
Allovate Therapeutics Provides Free Allerdent To Physicians
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of ...
-
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. “Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant ...
-
Aktivax wins $15 million contract with BARDA
[BOULDER, COLO] Aktivax, a Boulder County specialty pharmaceutical company, is expanding its team by more than 20 engineers and other technical staff after being awarded a Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Agency (BARDA) contract to continue developing its auto-injector platform ARAI. Under an 18-month, $15 million contract with BARDA, ...
-
Intrommune Therapeutics to Present at BIO Digital 2021
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. The event will be live June 10-11 & 14-18, 2021. Michael Nelson, JD, Co-Founder and CEO will provide an overview of ...
-
Intrommune Therapeutics Launches #PeanutAllergyStrong
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the launch of its #PeanutAllergyStrong patient engagement campaign. “Supporting peanut allergy patients and their loved ones has always been the central mission at ...
-
Allovate Therapeutics Appoints Bob Pomrenke as CEO
Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. ...
-
ROXALL Medizin acquires BIALs Allergene department
ROXALL Medizin in Hamburg and the Portuguese Pharma group BIAL have signed a contract. ROXALL takes over the allergy-section that, till now, was known as BIAL-Aristeguí. With this acquisition ROXALL provides the base for further growth. The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of ...
-
Dr. Hans van Schijndel appointed as Chief Research & Development Officer of HAL Allergy Holding B.V.
We are very pleased to announce that the Supervisory Board has appointed Dr. Hans van Schijndel as Member of the Board of HAL Allergy Holding B.V. in the position of Chief Research & Development Officer (Chief R&D Officer) as of 1 February 2020. With this appointment, the Board of Directors is now complete. Next to Dr. Hans van Schijndel, in charge of the R&D program, the Board ...
-
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the promotion of Sergi Trilla, MD to become Director of Corporate Strategy & Partnerships. “Dr. Trilla has proven to be an invaluable asset to Intrommune since he ...
-
Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Like Particles for Ultra-Fast Allergy Immunotherapy
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for Infection Research (HZI, Braunschweig, Germany) as part of ...
By Virometix AG
-
Vimian Group enters partnership with biotechnology company Angany Inc. to develop novel vaccines for allergy and atopic dermatitis in companion animals
Nextmune, the operating company within Vimian Group’s Specialty Pharma segment, has signed a development agreement with Angany Inc. Angany is a late pre-clinical stage biotechnology company dedicated to allergy treatments and immunotherapy for humans and animals. The company is based in Canada and started operations in 2018 under the leadership of Dr. Louis-Philippe Vézina, Ph.D. ...
By Angany Inc.
-
Angany and Lincoln Diagnostics to Collaborate on Angany’s Outreach to US Allergists
Louis-Philippe Vézina, CEO of Angany Inc. and Douglas Hein, President of Lincoln Diagnostics Inc. announce the commitment of their respective companies to collaborate on Angany’s outreach to US allergists. A formal agreement to this effect was signed earlier this year. Angany introduces a new approach to allergy immunotherapy based on translational science and designed to overcome ...
By Angany Inc.
-
HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene-Verordnung (TAV). The TAV was initiated by the German Federal Ministry of Health on 14 November, 2008, and regulates the marketing ...
-
Allovate and Restore Health Sign Exclusive Agreement to Bring Allerdent, the First Anti-Allergy Toothpaste System, to Allergy Sufferers
Allovate, LLC, a specialty biopharmaceutical company, today announced that the company has signed an exclusive provider agreement with Restore Health to bring the new Allerdent OMIT System™, a personalized toothpaste system for the delivery of allergy immunotherapy, to patients nationwide. Allerdent™ is the first oral mucosal immunotherapy (OMIT) toothpaste system designed to help ...
-
GI Innovation signed a contract with Medirama for joint research development of next generation innovative immuno-oncology
-GI Innovation-Medirama forms a ‘Joint Development Committee’ for professionalism maximization -Joint development for two new immuno-oncology… partial shared cooperative model of commercialization revenue GI Innovation, an innovative new drug development company signed a contract with Medirama, clinical development specialized company for joint research development of next ...
-
EU allergy and asthma network marks its achievements
The Global Allergy and Asthma European Network (GA2LEN)1, established in 2005 to facilitate excellence in allergy research across clinical and research institutions in Europe, has recently published a report on its major achievements. Funded by the EU, GA2LEN is composed of a multidisciplinary research network centred on scientific projects in allergy and asthma. It integrates research on ...
-
Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from top-tier investors and venture firms, including series A investors Khosla Ventures and Marc Benioff as well as new investors Seventure (Health for Life Capital ...
-
Siolta Therapeutics Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Siolta Therapeutics to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products. This new addition brings MTIG's membership to five companies pursuing regulatory approvals for microbiome therapeutics and microbiome-based products. Siolta ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you